Abstract
Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 880-885 |
Number of pages | 6 |
Journal | IDrugs |
Volume | 6 |
Issue number | 9 |
State | Published - Sep 1 2003 |
ASJC Scopus subject areas
- Pharmacology